US/UK/Canada

Share

Contacts

  • Nightingale Health
    Mannerheimintie 164A, 00300 Helsinki
    http://www.nightingalehealth.com

    • Quotes

    We cannot afford to continue shutting down economies going forward. Rather, we need to enable people to return safely to work and Nightingale’s solution is one of the first to allow targeted prevention before contracting the virus. This is a timely preventative screening tool as it enables the detection of the ones needing special precautions to avoid COVID-19 infection, while allowing the majority to return to work and help get the economy back to normal despite the pandemic.
    Teemu Suna, Founder and CEO of Nightingale Health
    The best way to detect those at high risk is by looking at a molecular signature of multiple biomarkers. It is striking that the risk identification works well even when focusing on a subset of biomarkers in Nightingale’s blood test that can be captured by self-collection through a finger prick blood sample. These novel findings provide a scalable solution for personalised prevention and population level screening, which can later also be used to prioritise vaccines for those who need it the most.
    Dr Peter Würtz, lead scientist of the study and Scientific Director of Nightingale Health
    While getting results requires substantial investments and patience, we have been eager from the very beginning to combine Nightingale’s blood biomarker data with one of the world’s largest health databases, the UK Biobank. We have firmly believed that the population-scale data will reveal a variety of novel medical findings, but the promising results on COVID-19 and pneumonia even surprised us.
    Teemu Suna, Founder and CEO of Nightingale Health.
    While vaccines and drugs play an important role with COVID-19, they are too late for many. Therefore, detecting and protecting the risk groups before they get exposed to the virus is one of the keys for effective COVID-19 strategy. Using the Nightingale blood biomarkers to identify vulnerable people could save lives as the tool could be used to isolate high-risk individuals. Once identified, the high-risk individuals are also able to take extra precautionary measures to protect themselves from the virus and eventually be prioritised for novel vaccines produced at limited capacity.
    Teemu Suna, Founder and CEO of Nightingale Health.
    The initial findings by Nightingale’s scientists for COVID-19 and pneumonia must naturally be validated but they show great promise. By joint studies of many European cohorts, we have previously made landmark scientific findings with the Nightingale blood biomarkers as indicators of physiological and mental vulnerability. With the UK Biobank data, we strongly believe that many novel findings are waiting to be discovered. We are very excited to collaborate with Nightingale around the very promising results with COVID-19 and pneumonia.
    Dr Eline Slagboom, Professor of molecular epidemiology at the Leiden University Medical Center
    The initial results with COVID-19 and pneumonia by combining Nightingale technology and the UK Biobank are truly exciting and very timely. However, this is just the tip of the iceberg. We have completed the first batch of 125,000 samples and I’m expecting a wealth of novel findings in the near future while we continue the blood sample analyses up to 500,000 UK Biobank samples. The power of large-scale population data is immense and I’m very proud to see how Nightingale’s technology and our collaboration with the world-leading scientists are paving the way towards better global health solutions.
    Dr Peter Würtz, Founder and Scientific Director of Nightingale Health
    Nightingale's core strategy lies in the intersection of science and preventative health applications. We believe that brings benefits in the form of new scientific findings but simultaneously also help people have healthier lives.
    Teemu Suna, Founder and CEO, Nightingale Health
    We are pleased that these well-renowned scientists will help us strengthen the science emerging from our global biobank initiatives. Nightingale remains committed to taking our innovative biomarker offerings beyond applications for population health research with the strongest possible scientific underpinnings.
    Dr Peter Würtz, Scientific Director and Co-founder, Nightingale Health.   
    We are delighted to have Mr. Närhinen as an investor, but more importantly, we are very honoured to have one of the most experienced healthcare professionals in Europe to support us in taking Nightingale’s technology to global healthcare markets.
    Teemu Suna, Founder and CEO, Nightingale Health
    In order to improve healthcare in large scale, we need practical tools that enable early detection and active prevention of chronic diseases. Nightingale’s blood testing technology has the potential of being the game changer in this regard, enabling truly preventative healthcare for people.
    Yrjö Närhinen
    I want to share my connections and experience in growing major healthcare business with Nightingale’s top management and the Board of directors. They have an unprecedented opportunity to shape the future of global healthcare with their technology
    Yrjö Närhinen
    Having Mr. Närhinen as a strategic advisor with an independent perspective will significantly help Nightingale to focus on the most promising international market opportunities. With our proven world-leading technology and exceptional team, we are in an excellent position to rapidly grow our business and continue our journey in helping everyone to live and extend healthy life
    Teemu Suna, Founder and CEO, Nightingale Health
    Abolishing chronic diseases demands democratising preventive health. Nightingale therefore wants to give people the best possible tools to take care of their health. Our mission is to build a health-creation system enabling a preventive health journey for everyone.
    Teemu Suna, Founder & CEO, Nightingale Health
    We are giving individuals access to health information that was previously available only for scientists. That’s because our aim is to equip people with the best tools that can help them increase their health spans and live healthy lives.
    Teemu Suna, Founder and Chief Executive Officer of Nightingale Health
    Imagine, if personal success stories in improving health from around the world could benefit thousands of others in similar health situations. We foresee a future where knowledge of health doesn’t remain in silos but is shared to create collective knowledge that benefits the health of individuals, communities and the whole society.
    Teemu Suna, Founder and Chief Executive Officer of Nightingale Health
    Our global position in scientific validation, technology readiness, regulative approvals and product availability is extremely good and in many areas second to none. Creating biotechnology based health solutions for mass-market is one of the most challenging tasks there is, but the Nightingale Team has made it –– and now we are ready to scale out.
    Teemu Suna, founder and Chief Executive Officer of Nightingale Health
    We are pleased to announce this strategic partnership with Nightingale to bring preventative health and wellness solutions together with our partner company Kirin
    Toshitaka Inuzuka, General Manager, NutriScience Division, Mitsui
    I believe Nightingale’s blood-test provides very valuable biomarker information about health in chronic diseases. When integrating the biomarkers with multiple health-related data sources and machine learning, we will have crucial knowledge to develop new nutritional products
    Toru Yoshimura, Senior Executive Officer, Kirin Holdings
    Our research will give new insights into the metabolic disturbances that precede and predict diabetes in Asian populations. We hope that this will enable us to better understand disease pathways, and to develop new approaches for identification of high-risk South Asian people who may benefit from early intervention.
    Professor John Chambers, Imperial College London
    Traditionally, technological constraints and high costs have impeded researchers from doing such large-scale population analysis. We are happy to provide a technology that can measure over 220 metabolic biomarkers from a single blood sample at very reasonable costs. This supports scientists to make massive breakthroughs in medical science.
    Teemu Suna, CEO, Founder, Nightingale Health
    We face a huge challenge with the athletes training for international games like the Olympics or other world championships as, very often, they fall ill right before a big competition and a lot of the work goes to waste. However, currently, we don’t have enough knowledge around respiratory infections and immunology in sports medicine to be able to prevent and truly understand such a scenario.
    Dr Maarit Valtonen, the lead MD (Doctor of Medicine) for the Finnish Olympic Team
    I have had to deal with infections on several occasions earlier in my career. The situation is more stable now, but I really hope that the study results will be able to guide athletes on how to take better care of themselves and improve performance.
    Laura Mononen, an Olympic cross-country skier
    Nightingale’s technology is not only versatile but pioneering in preventive care as it offers details about your health that was not revealed to you before. This will give everyone a chance to improve their lifestyle and live healthier lives.
    Teemu Suna, founder and CEO of Nightingale Health
    Nightingale has been involved in some of the world’s largest metabolomics projects, including being selected to analyse the entire UK Biobank cohort of 500 000 samples, the national biobank of Finland (THL Biobank) and the Mexico City Prospective Cohort in coordination with Oxford University. We’re now looking to expand the use of our platform with ground-breaking initiatives in the U.S., and further enhance public health research with large studies worldwide
    Dr Peter Würtz, Scientific Director and Co-founder at Nightingale Health
    We are pleased that Nightingale selected our clinical laboratory in Pittsburgh to expand its innovative biomarker analysis offering to customers here in the U.S.
    Dr. Madhuri Hegde, Vice President and Chief Scientific Officer, PerkinElmer Genomics
    The Singapore Multiethnic Cohort creates a unique research setting to study how to improve the prediction of type 2 diabetes, coronary artery calcification, and changes in cardiovascular risk factors in the Singaporean population. Nightingale’s technology creates a novel opportunity to look at a broad profile of metabolic markers, potentially enhancing the understanding of disease development.
    Professor Tai E Shyong, the Department of Medicine, Yong Loo Lin School of Medicine, NUS and the Saw Swee Hock School of Public Health, NUS
    It’s an interesting opportunity to examine how these biomarkers are associated with dietary and other lifestyle factors and may mediate associations between lifestyle factors, cardiovascular disease risk factors, and risk of type 2 diabetes. Moreover, potential biomarker associations can be replicated with other studies around the world carried out using Nightingale’s technology, enabling more detailed analysis of the findings in Singapore.
    Professor Rob M. van Dam, Saw Swee Hock School of Public Health, NUS
    Nightingale’s blood analysis technology is a global platform. This means that samples measured with our technology all over the world can be combined, compared and replicated. We are excited about this initiative with NUS, as it brings large-scale Southeast Asian sample collections to an international platform, benefitting medical researchers in Singapore and South East Asia but also having a global impact.
    Teemu Suna, CEO and Founder, Nightingale Health
    Nightingale is committed to continuous improvement and nowhere is this more important than in delivering our clinical service to the highest standard.
    Marjut Vähäheikkilä, Head of Health, Safety, Environment and Quality, Nightingale Health
    From the beginning we’ve put quality and the needs of regulatory requirements at the centre of our strategy.
    Teemu Suna, Founder and CEO, Nightingale Health
    Chronic diseases are a nightmare, not only for those who suffer from them, but also for those trying to cure them. The EIB is committed to supporting companies like Nightingale that can realistically make a big impact and improve the health of EU citizens. The support of the Investment Plan for Europe is particularly valuable here, and the operation is fully aligned with the objective of supporting high-skilled employment opportunities. This will also enhance Europe’s position as a major leader in medical innovation.
    EIB Vice-President Alexander Stubb
    Europe invests heavily in education and science as we believe that putting a strategic effort into these areas can reap huge benefits. This commitment has resulted in Europe’s position today as a world leader in cutting edge medical research. We are delighted that the Investment Plan for Europe is fostering the development of Nightingale’s technology which has the potential to add significant value to European healthcare.
    European Commission Vice-President Jyrki Katainen
    Nightingale wants to create a world where healthcare keeps people healthy throughout their lifetimes, not just whenever they get sick. When we founded Nightingale in 2013, we wanted to bring together innovations from biotechnology, medicine and computer sciences to build a different type of healthcare – one where everyone is given a chance to live a healthier life. Today’s announcement provides Nightingale with the funding needed to take our vision for personalized medicine into European healthcare. By supplying physicians with accurate chronic disease risk prediction for their patients, we will empower people to better understand their own health status and take actions to reduce their risk. Not only will this transform how we treat common diseases such as diabetes and heart disease, but it will also significantly reduce the current economic burden on healthcare systems and workforces.
    Nightingale Health CEO and Founder Teemu Suna
    In addition to treating the symptoms and complications of diseases like type 2 diabetes, we should be equipping people with the best possible tools to keep themselves healthier for longer, and making them available at an affordable price. Virta 360 is a health concept for the 21st century. By combining molecular insights related to physical health with advanced digital health applications that measure lifestyle habits, we can better understand a person’s overall health status and allow them to proactively improve their wellbeing.
    Teemu Suna, Founder and CEO, Nightingale Health
    An individual’s wellbeing is influenced by all aspects of their life, from nutrition to personal relationships. These are reflected by changes in a person’s blood, providing an indication of their future wellbeing. Virta 360, for the very first time, allows people to fully understand how their lifestyle habits are impacting their health and provides them with better tools to keep their wellbeing on track.
    Lauri Muhonen, Chief Digital Officer, Aava
    As we have seen in numerous studieswith thousands of study volunteers,GlycA has considerable potential as a marker of chronic inflammation that can effectively predict disease onset and prognosis. The findings of this paper add further evidence to support the measurement of GlycA in national biobanks, as well as its utility in future clinical applications
    Dr. Peter Würtz, Scientific Director, Nightingale Health
    Nightingale’s mission is strongly linked to scientific evidence generation. This means working with world-leading institutions and biosample collections to continuously improve the understanding of health and disease. Our aim is to translate this understanding into improved early prediction of diabetes and cardiovascular diseases, achieving better healthcare for everyone. Our initiative with the UK Biobank demonstrates Nightingale’s unwavering commitment towards supporting innovative medical science carried out by researchers from across the world.
    Teemu Suna, CEO and Founder, Nightingale Health
    We are delighted to see these novel blood sample analyses being done in UK Biobank. We already have an enormous amount of information about the lifestyles and genetic make-up of the participants in UK Biobank, as well as about their health, and are currently conducting imaging studies of their brains, hearts and bodies. Providing the medical research community with these additional high quality metabolic biomarker data on such a large scale will enhance discovery science and population science, providing opportunities to benefit patient care and public health.
    Professor Sir Rory Collins, UK Biobank’s Principal Investigator
    Analysing 500,000 blood samples from a single study with Nightingale’s comprehensive biomarker profiling technology allows us to uncover metabolic signatures that reflect a risk for future disease onset, as well as their underlying risk factors. We anticipate this detailed molecular readout of the health state, combining both lifestyle and genetic makeup, will result in a wealth of scientific applications from the research community. This will be relevant not only to the British population but also yield ground-breaking science and enhanced drug development opportunities with a global public health impact.
    Dr. Peter Würtz, Scientific Director and Founder, Nightingale Health
    We are excited to be able to expand our metabolomics offerings in the fall of 2018. Our urine, cerebrospinal fluid (CSF) and umbilical cord blood services will allow us to provide researchers with a pervasive and more complete picture of human health. The ability to compare changes in the metabolic profiles of the different bio-fluids is especially interesting and will further the molecular understanding of health and disease.
    Teemu Suna, CEO and Founder, Nightingale Health.
    "We believe that our technology will provide better tools for the prevention of chronic diseases in primary care. Solving the prevailing issues in healthcare today requires the development of cutting-edge innovations and the courage to take advantage of the possibilities they bring. We are honored to receive this award and industry support, as we continue to make strides towards bringing our service to healthcare systems globally.”
    Teemu Suna, CEO and Founder, Nightingale Health
    We’re proud to have received recognition from the Health Awards jury for our impact on the current debate taking place in the Finnish healthcare sector. As innovators in the healthcare space we aim to switch the primary strategy of the current system from disease treatment to disease prevention, replacing routinely used cholesterol tests worldwide.
    Teemu Suna, CEO, Founder & Chairman, Nightingale Health
    It’s an honor to receive recognition from EuropaBio’s jury panel of biotech experts and be invited to speak at the EU parliament. We believe our blood analysis technology has the potential to make a considerable contribution to society through improving early disease detection in healthcare, particularly in primary care. By allowing patients to take an active role in their own health maintenance, we can switch the focus in healthcare from treatment to prevention
    Nightingale Health, CEO and Founder, Teemu Suna
    "Coronaria  aims to  build a novel healthcare system  in  Finland  that will benefit  all  of us, with  patients receiving  better care, personnel  achieving more and  society saving  money. The emphasis in healthcare  must be shifted to preventive and  personalized  care, especially  for  chronic disease  treatments. We see Nightingale's blood analysis as  an  important tool to achieve this  goal.  As a result, we wanted  to be  the  first  to  pilot the service in Finland",
    Olli Karhi, Coronaria, Cor Group
    "The only sustainable way to reduce the burden of chronic diseases is to invest in their prevention. The goal of this cooperative  pilot with  Coronaria  is to prove Nightingale's technology's suitability  for  routine  clinical  use"
    Teemu Suna, CEO, Co-founder, Nightingale Health
    We believe that our technology takes us one step closer to better prevention of chronic diseases. Therefore, we see this as a notable milestone, not only for our company but also for preventive medicine.
    Teemu Suna, Nightingale Health
    This is an excellent opportunity for us to use Nightingale’s bioanalysis platform, which can provide much more data for a relatively small amount of sample than current methods. Ultimately this data will allow us to better understand and treat chronic conditions.
    The NDPH Wolfson Laboratories Scientific Director, Michael Hill
    “We are excited to bring our metabolic profiling technology available on-site at University of Oxford to be utilised for world-class science. The possibility to run routinely and cost-effectively any number of blood samples to gather extensive quantitative metabolic biomarker data creates an unprecedented opportunity for research and clinical applications.
    Teemu Suna, CEO, Nightingale Health
    Pick a time period -
    Tags ( Active)
    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media